Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Ames

Showing results (371-380 of 416) with videos related to

Pageof 42
Sort By:
Investigational New Drugs|October 12, 2013
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabineMatthew P Goetz, Heidi A McKean, Joel M Reid, et al.
Cancer Research|March 15, 2008
Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agentChitta Ranjan Patra, Resham Bhattacharya, Enfeng Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashesMatthew P Goetz, James M Rae, Vera J Suman, et al.
Investigational New Drugs|May 13, 2010
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumorsMark Andrew Dickson, Dana E Rathkopf, Richard D Carvajal, et al.
Pharmacogenetics and Genomics|February 26, 2015
Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifenStephanie L Safgren, Vera J Suman, Matthew L Kosel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2001
A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicitiesF Bracho, M D Krailo, V Shen, et al.
The Journal of Biological Chemistry|January 11, 2007
Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicitySon B Le, M Katie Hailer, Sarah Buhrow, et al.
Cancer Chemotherapy and Pharmacology|May 6, 2010
Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in miceJan H Beumer, Julie L Eiseman, Judith A Gilbert, et al.
Clinical Pharmacology and Therapeutics|November 1, 2007
Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamideR M Myers, S M Greiner, M E Harvey, et al.
Molecular Ecology|August 28, 2023
Novel insights into symbiont population structure: Globe-trotting avian feather mites contradict the specialist-generalist variation hypothesisAlix E Matthews, Than J Boves, Andrew D Sweet, et al.
Pageof 42

Showing results (371-380 of 416) with videos related to

Sort By:
Pageof 42
Investigational New Drugs|October 12, 2013
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabineMatthew P Goetz, Heidi A McKean, Joel M Reid, et al.
Cancer Research|March 15, 2008
Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agentChitta Ranjan Patra, Resham Bhattacharya, Enfeng Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2005
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashesMatthew P Goetz, James M Rae, Vera J Suman, et al.
Investigational New Drugs|May 13, 2010
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumorsMark Andrew Dickson, Dana E Rathkopf, Richard D Carvajal, et al.
Pharmacogenetics and Genomics|February 26, 2015
Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifenStephanie L Safgren, Vera J Suman, Matthew L Kosel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2001
A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicitiesF Bracho, M D Krailo, V Shen, et al.
The Journal of Biological Chemistry|January 11, 2007
Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicitySon B Le, M Katie Hailer, Sarah Buhrow, et al.
Cancer Chemotherapy and Pharmacology|May 6, 2010
Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in miceJan H Beumer, Julie L Eiseman, Judith A Gilbert, et al.
Clinical Pharmacology and Therapeutics|November 1, 2007
Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamideR M Myers, S M Greiner, M E Harvey, et al.
Molecular Ecology|August 28, 2023
Novel insights into symbiont population structure: Globe-trotting avian feather mites contradict the specialist-generalist variation hypothesisAlix E Matthews, Than J Boves, Andrew D Sweet, et al.
Pageof 42